Twist Bioscience (TWST) EBITDA (2017 - 2026)

Twist Bioscience has disclosed EBITDA across 10 years of filings, most recently posting -$44.1 million for Q1 2026.

• In Q1 2026, EBITDA fell 12.12% year-over-year to -$44.1 million; the TTM figure through Mar 2026 stood at -$81.3 million (up 57.49% YoY), while the FY2025 annual figure was -$77.8 million, up 62.7% from the prior year.
• EBITDA declined to -$44.1 million in Q1 2026, from -$30.5 million in the prior quarter.
• Over the last five years, EBITDA for TWST reached as high as $20.2 million in Q2 2025 and fell as low as -$85.6 million in Q2 2024.
• The 5-year median for EBITDA is -$44.1 million (2026), against an average of -$43.6 million.
• Annual changes were most pronounced in 2022 — EBITDA slumped 62.41% — and 2025, when it soared 123.57%.
• A 5-year view of EBITDA shows it stood at -$43.1 million in 2022, then gained by 0.56% to -$42.8 million in 2023, then grew by 25.91% to -$31.7 million in 2024, then grew by 4.0% to -$30.5 million in 2025, then plunged by 44.79% to -$44.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$44.1 million, -$30.5 million, and -$26.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.